-
Je něco špatně v tomto záznamu ?
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
RJ. Sylvester, O. Rodríguez, V. Hernández, D. Turturica, L. Bauerová, HM. Bruins, J. Bründl, TH. van der Kwast, A. Brisuda, J. Rubio-Briones, M. Seles, AE. Hentschel, VRM. Kusuma, N. Huebner, J. Cotte, LS. Mertens, D. Volanis, O. Cussenot, JD....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
- MeSH
- invazivní růst nádoru MeSH
- lidé MeSH
- nádory močového měchýře * terapie MeSH
- prognóza MeSH
- retrospektivní studie MeSH
- Světová zdravotnická organizace MeSH
- urologie * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. OBJECTIVE: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. INTERVENTION: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. RESULTS AND LIMITATIONS: A total of 3401 patients treated with TURBT ± intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. CONCLUSIONS: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for which urologists should be prompt to assess and adapt their therapeutic strategy when necessary. PATIENT SUMMARY: The newly updated European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer provide an improved basis for recommending a patient's treatment and follow-up schedule.
Department of Health Evidence Radboud University Medical Center Nijmegen The Netherlands
Department of Pathology Caritas St Josef Medical Center University of Regensburg Regensburg Germany
Department of Pathology Fundacio Puigvert Universitat Autònoma de Barcelona Barcelona Spain
Department of Pathology Fundación Instituto Valenciano de Oncología Valencia Spain
Department of Pathology Hospital Universitario Fundación Alcorcón Madrid Spain
Department of Pathology Medical University of Graz Graz Austria
Department of Pathology Radboud University Medical Center Nijmegen The Netherlands
Department of Pathology Royal Free London NHS Foundation Trust Royal Free Hospital London UK
Department of Pathology Tenon Hospital AP HP Sorbonne University Paris France
Department of Urology Caritas St Josef Medical Center University of Regensburg Regensburg Germany
Department of Urology Fundacio Puigvert Universitat Autònoma de Barcelona Barcelona Spain
Department of Urology Fundación Instituto Valenciano de Oncología Valencia Spain
Department of Urology Hospital Universitario Fundación Alcorcón Madrid Spain
Department of Urology Medical University of Graz Graz Austria
Department of Urology Pitié Salpétrière Hospital AP HP Sorbonne University Paris France
Department of Urology Radboud University Medical Center Nijmegen The Netherlands
Department of Urology Royal Free London NHS Foundation Trust Royal Free Hospital London UK
Department of Urology Tenon Hospital AP HP Sorbonne University Paris France
Department of Urology The Stokes Centre for Urology Royal Surrey Hospital Guildford UK
European Association of Urology Guidelines Office Arnhem The Netherlands
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22012488
- 003
- CZ-PrNML
- 005
- 20220506125906.0
- 007
- ta
- 008
- 220425s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2020.12.033 $2 doi
- 035 __
- $a (PubMed)33419683
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Sylvester, Richard J $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Electronic address: richard.sylvester@skynet.be
- 245 10
- $a European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel / $c RJ. Sylvester, O. Rodríguez, V. Hernández, D. Turturica, L. Bauerová, HM. Bruins, J. Bründl, TH. van der Kwast, A. Brisuda, J. Rubio-Briones, M. Seles, AE. Hentschel, VRM. Kusuma, N. Huebner, J. Cotte, LS. Mertens, D. Volanis, O. Cussenot, JD. Subiela Henríquez, E. de la Peña, F. Pisano, M. Pešl, AG. van der Heijden, S. Herdegen, AR. Zlotta, J. Hacek, A. Calatrava, S. Mannweiler, J. Bosschieter, D. Ashabere, A. Haitel, JF. Côté, S. El Sheikh, L. Lunelli, F. Algaba, I. Alemany, F. Soria, W. Runneboom, J. Breyer, JA. Nieuwenhuijzen, C. Llorente, L. Molinaro, CA. Hulsbergen-van de Kaa, M. Evert, LALM. Kiemeney, J. N'Dow, K. Plass, O. Čapoun, V. Soukup, JL. Dominguez-Escrig, D. Cohen, J. Palou, P. Gontero, M. Burger, R. Zigeuner, AH. Mostafid, SF. Shariat, M. Rouprêt, EM. Compérat, M. Babjuk, BWG. van Rhijn
- 520 9_
- $a BACKGROUND: The European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) are used to provide recommendations for patient treatment after transurethral resection of bladder tumor (TURBT). They do not, however, take into account the widely used World Health Organization (WHO) 2004/2016 grading classification and are based on patients treated in the 1980s. OBJECTIVE: To update EAU prognostic factor risk groups using the WHO 1973 and 2004/2016 grading classifications and identify patients with the lowest and highest probabilities of progression. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data for primary NMIBC patients were collected from the institutions of the members of the EAU NMIBC guidelines panel. INTERVENTION: Patients underwent TURBT followed by intravesical instillations at the physician's discretion. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Multivariable Cox proportional-hazards regression models were fitted to the primary endpoint, the time to progression to muscle-invasive disease or distant metastases. Patients were divided into four risk groups: low-, intermediate-, high-, and a new, very high-risk group. The probabilities of progression were estimated using Kaplan-Meier curves. RESULTS AND LIMITATIONS: A total of 3401 patients treated with TURBT ± intravesical chemotherapy were included. From the multivariable analyses, tumor stage, WHO 1973/2004-2016 grade, concomitant carcinoma in situ, number of tumors, tumor size, and age were used to form four risk groups for which the probability of progression at 5 yr varied from <1% to >40%. Limitations include the retrospective collection of data and the lack of central pathology review. CONCLUSIONS: This study provides updated EAU prognostic factor risk groups that can be used to inform patient treatment and follow-up. Incorporating the WHO 2004/2016 and 1973 grading classifications, a new, very high-risk group has been identified for which urologists should be prompt to assess and adapt their therapeutic strategy when necessary. PATIENT SUMMARY: The newly updated European Association of Urology prognostic factor risk groups for non-muscle-invasive bladder cancer provide an improved basis for recommending a patient's treatment and follow-up schedule.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a nádory močového měchýře $x terapie $7 D001749
- 650 12
- $a urologie $7 D014572
- 650 _2
- $a Světová zdravotnická organizace $7 D014944
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rodríguez, Oscar $u Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Hernández, Virginia $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
- 700 1_
- $a Turturica, Diana $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Bauerová, Lenka $u Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Bruins, Harman Max $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Bründl, Johannes $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a van der Kwast, Theo H $u Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada
- 700 1_
- $a Brisuda, Antonin $u Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Rubio-Briones, José $u Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Seles, Maximilian $u Department of Urology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Hentschel, Anouk E $u Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Kusuma, Venkata R M $u Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Huebner, Nicolai $u Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Cotte, Juliette $u Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France
- 700 1_
- $a Mertens, Laura S $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Volanis, Dimitrios $u Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK
- 700 1_
- $a Cussenot, Olivier $u Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK
- 700 1_
- $a Subiela Henríquez, Jose D $u Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a de la Peña, Enrique $u Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
- 700 1_
- $a Pisano, Francesca $u Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Pešl, Michael $u Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a van der Heijden, Antoine G $u Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Herdegen, Sonja $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Zlotta, Alexandre R $u Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada
- 700 1_
- $a Hacek, Jaromir $u Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Calatrava, Ana $u Department of Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Mannweiler, Sebastian $u Department of Pathology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Bosschieter, Judith $u Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands
- 700 1_
- $a Ashabere, David $u Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Haitel, Andrea $u Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Côté, Jean-François $u Department of Pathology, Pitié Salpétrière Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France
- 700 1_
- $a El Sheikh, Soha $u Department of Pathology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK
- 700 1_
- $a Lunelli, Luca $u Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France
- 700 1_
- $a Algaba, Ferran $u Department of Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Alemany, Isabel $u Department of Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
- 700 1_
- $a Soria, Francesco $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Runneboom, Willemien $u Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Breyer, Johannes $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Nieuwenhuijzen, Jakko A $u Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands
- 700 1_
- $a Llorente, Carlos $u Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
- 700 1_
- $a Molinaro, Luca $u Department of Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Hulsbergen-van de Kaa, Christina A $u Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Evert, Matthias $u Department of Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Kiemeney, Lambertus A L M $u Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a N'Dow, James $u European Association of Urology Guidelines Office, Arnhem, The Netherlands
- 700 1_
- $a Plass, Karin $u European Association of Urology Guidelines Office, Arnhem, The Netherlands
- 700 1_
- $a Čapoun, Otakar $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Soukup, Viktor $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic
- 700 1_
- $a Dominguez-Escrig, Jose L $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Cohen, Daniel $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK
- 700 1_
- $a Palou, Joan $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain
- 700 1_
- $a Gontero, Paolo $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Burger, Maximilian $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany
- 700 1_
- $a Zigeuner, Richard $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria
- 700 1_
- $a Mostafid, Amir Hugh $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK
- 700 1_
- $a Shariat, Shahrokh F $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a Rouprêt, Morgan $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France
- 700 1_
- $a Compérat, Eva M $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France
- 700 1_
- $a Babjuk, Marko $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria
- 700 1_
- $a van Rhijn, Bas W G $u European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 79, č. 4 (2021), s. 480-488
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33419683 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506125858 $b ABA008
- 999 __
- $a ok $b bmc $g 1789897 $s 1163689
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 79 $c 4 $d 480-488 $e 20210106 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20220425
